Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer.
Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S, Vergote I, Calvert H, Jacobs IJ, Widschwendter M. Teschendorff AE, et al. Among authors: dubeau l. Genome Med. 2015 Oct 24;7:108. doi: 10.1186/s13073-015-0233-4. Genome Med. 2015. PMID: 26497652 Free PMC article.
HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study.
Widschwendter M, Apostolidou S, Jones AA, Fourkala EO, Arora R, Pearce CL, Frasco MA, Ayhan A, Zikan M, Cibula D, Iyibozkurt CA, Yavuz E, Hauser-Kronberger C, Dubeau L, Menon U, Jacobs IJ. Widschwendter M, et al. Among authors: dubeau l. Int J Cancer. 2009 Nov 1;125(9):2214-8. doi: 10.1002/ijc.24599. Int J Cancer. 2009. PMID: 19621443 Free article.
Genome-scale screen for DNA methylation-based detection markers for ovarian cancer.
Campan M, Moffitt M, Houshdaran S, Shen H, Widschwendter M, Daxenbichler G, Long T, Marth C, Laird-Offringa IA, Press MF, Dubeau L, Siegmund KD, Wu AH, Groshen S, Chandavarkar U, Roman LD, Berchuck A, Pearce CL, Laird PW. Campan M, et al. Among authors: dubeau l. PLoS One. 2011;6(12):e28141. doi: 10.1371/journal.pone.0028141. Epub 2011 Dec 7. PLoS One. 2011. PMID: 22163280 Free PMC article.
The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.
Widschwendter M, Rosenthal AN, Philpott S, Rizzuto I, Fraser L, Hayward J, Intermaggio MP, Edlund CK, Ramus SJ, Gayther SA, Dubeau L, Fourkala EO, Zaikin A, Menon U, Jacobs IJ. Widschwendter M, et al. Among authors: dubeau l. Lancet Oncol. 2013 Nov;14(12):1226-32. doi: 10.1016/S1470-2045(13)70448-0. Epub 2013 Oct 17. Lancet Oncol. 2013. PMID: 24140203 Free article.
Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.
Widschwendter M, Burnell M, Fraser L, Rosenthal AN, Philpott S, Reisel D, Dubeau L, Cline M, Pan Y, Yi PC, Gareth Evans D, Jacobs IJ, Menon U, Wood CE, Dougall WC. Widschwendter M, et al. Among authors: dubeau l. EBioMedicine. 2015 Sep 9;2(10):1331-9. doi: 10.1016/j.ebiom.2015.08.037. eCollection 2015 Oct. EBioMedicine. 2015. PMID: 26629528 Free PMC article.
Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.
Kiechl S, Schramek D, Widschwendter M, Fourkala EO, Zaikin A, Jones A, Jaeger B, Rack B, Janni W, Scholz C, Willeit J, Weger S, Mayr A, Teschendorff A, Rosenthal A, Fraser L, Philpott S, Dubeau L, Keshtgar M, Roylance R, Jacobs IJ, Menon U, Schett G, Penninger JM. Kiechl S, et al. Among authors: dubeau l. Oncotarget. 2017 Jan 17;8(3):3811-3825. doi: 10.18632/oncotarget.14013. Oncotarget. 2017. PMID: 28002811 Free PMC article.
110 results